HIV Research Lab


Over the years, we have partnered and continue to work closely with the National Institutes of Health-funded DC CFAR, MedStar Washington Hospital Center and George Washington University.

Special Immunology Services is excited to announce our partnership with Merck & Co. in an upcoming trial: A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Pediatric Participants with HIV-1 Infection who are Virologically Suppressed or Treatment-Naïve, are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg. Approximate trial duration will be 96 weeks. Trial initiation will begin early 2021.